These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32538866)

  • 1. Clinical Progression of Parkinson's Disease: Insights from the NINDS Common Data Elements.
    Lewis MM; Harkins E; Lee EY; Stetter C; Snyder B; Corson T; Du G; Kong L; Huang X
    J Parkinsons Dis; 2020; 10(3):1075-1085. PubMed ID: 32538866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease: Secondary Analysis of Longitudinal Data From NINDS Exploratory Trials in Parkinson Disease Long-term Study 1.
    Wills AM; Pérez A; Wang J; Su X; Morgan J; Rajan SS; Leehey MA; Pontone GM; Chou KL; Umeh C; Mari Z; Boyd J;
    JAMA Neurol; 2016 Mar; 73(3):321-8. PubMed ID: 26751506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of prodromal parkinsonian features in a cohort of
    Avenali M; Toffoli M; Mullin S; McNeil A; Hughes DA; Mehta A; Blandini F; Schapira AHV
    J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1091-1097. PubMed ID: 31221723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Key Determinants to Quality of Life in Parkinson's Disease Patients: Results from the Parkinson's Disease Biomarker Program (PDBP).
    He L; Lee EY; Sterling NW; Kong L; Lewis MM; Du G; Eslinger PJ; Huang X
    J Parkinsons Dis; 2016 May; 6(3):523-32. PubMed ID: 27258700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of the Rapid Progression in Prodromal Parkinson's Disease: A Longitudinal Follow-Up Study.
    Liu P; Chen L; He X; Mao L
    Gerontology; 2024; 70(6):595-602. PubMed ID: 38565088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.
    Regnault A; Boroojerdi B; Meunier J; Bani M; Morel T; Cano S
    J Neurol; 2019 Aug; 266(8):1927-1936. PubMed ID: 31073716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
    Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
    Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.
    Parashos SA; Luo S; Biglan KM; Bodis-Wollner I; He B; Liang GS; Ross GW; Tilley BC; Shulman LM;
    JAMA Neurol; 2014 Jun; 71(6):710-6. PubMed ID: 24711047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olfactory Impairment Is the Main Predictor of Higher Scores at REM Sleep Behavior Disorder (RBD) Screening Questionnaire in Parkinson's Disease Patients.
    Solla P; Wang Q; Frau C; Floris V; Loy F; Sechi LA; Masala C
    Brain Sci; 2023 Mar; 13(4):. PubMed ID: 37190564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients.
    Martínez-Martín P; Rodríguez-Blázquez C; Forjaz MJ; Alvarez-Sánchez M; Arakaki T; Bergareche-Yarza A; Chade A; Garretto N; Gershanik O; Kurtis MM; Martínez-Castrillo JC; Mendoza-Rodríguez A; Moore HP; Rodríguez-Violante M; Singer C; Tilley BC; Huang J; Stebbins GT; Goetz CG
    Eur J Neurol; 2014 Mar; 21(3):519-24. PubMed ID: 24447695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson's Disease Progression and Statins: Hydrophobicity Matters.
    Lewis MM; Albertson RM; Du G; Kong L; Foy A; Huang X
    J Parkinsons Dis; 2022; 12(3):821-830. PubMed ID: 34958045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative mobility measures complement the MDS-UPDRS for characterization of Parkinson's disease heterogeneity.
    Hill EJ; Mangleburg CG; Alfradique-Dunham I; Ripperger B; Stillwell A; Saade H; Rao S; Fagbongbe O; von Coelln R; Tarakad A; Hunter C; Dawe RJ; Jankovic J; Shulman LM; Buchman AS; Shulman JM
    Parkinsonism Relat Disord; 2021 Mar; 84():105-111. PubMed ID: 33607526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysosmia Is a Predictor of Motor Function and Quality of Life in Patients with Parkinson's Disease.
    Lin CY; Chang TY; Chang MH
    J Pers Med; 2022 May; 12(5):. PubMed ID: 35629176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the relationship between non-motor symptoms and health-related quality of life in Parkinson's disease: a retrospective observational cohort study.
    Ueno T; Kon T; Haga R; Nishijima H; Arai A; Tomiyama M
    Neurol Sci; 2020 Oct; 41(10):2867-2873. PubMed ID: 32328832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort.
    Beavan M; McNeill A; Proukakis C; Hughes DA; Mehta A; Schapira AH
    JAMA Neurol; 2015 Feb; 72(2):201-8. PubMed ID: 25506732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyposmia as a marker of (non-)motor disease severity in Parkinson's disease.
    Roos DS; Twisk JWR; Raijmakers PGHM; Doty RL; Berendse HW
    J Neural Transm (Vienna); 2019 Nov; 126(11):1471-1478. PubMed ID: 31515655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between the MNCD classification-based staging of Parkinson's disease and quality of life: a cross-sectional study.
    He G; Ren J; Shi H; Liu W; Lu M
    J Neural Transm (Vienna); 2024 Apr; 131(4):315-322. PubMed ID: 38548920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The clinical efficacy of the stratification medical treatment based on the risk estimation of motor complications in Parkinson's disease].
    Wan Y; Xiao RQ; Zhao JH; Zhang Y; Gan J; Wu N; Song L; Li L; Qi C; Chen W; Wang XJ; Liu ZG
    Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(7):491-498. PubMed ID: 35184502
    [No Abstract]   [Full Text] [Related]  

  • 19. Sequential change in olfaction and (non) motor symptoms: the difference between anosmia and non-anosmia in Parkinson's disease.
    Fang TC; Tsai YS; Chang MH
    Front Aging Neurosci; 2023; 15():1213977. PubMed ID: 37533763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Segmental progression of early untreated Parkinson's disease: a novel approach to clinical rating.
    Schüpbach WM; Corvol JC; Czernecki V; Djebara MB; Golmard JL; Agid Y; Hartmann A
    J Neurol Neurosurg Psychiatry; 2010 Jan; 81(1):20-5. PubMed ID: 19622523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.